<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">657033</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.657033</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Mechanisms of Modulation of Ferroptosis and Its Role in Central Nervous System Diseases</article-title>
<alt-title alt-title-type="left-running-head">Tan et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Ferroptosis Mechanisms and CNS Diseases</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Qingyun</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fang</surname>
<given-names>Yuying</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gu</surname>
<given-names>Qiong</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/590628/overview"/>
</contrib>
</contrib-group>
<aff>Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<corresp id="c001">&#x2a;Correspondence: Qiong Gu, <email>guqiong@mail.sysu.edu.cn</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/269274/overview">Philippe De Deurwaerdere</ext-link>, Universit&#xe9; de Bordeaux, France</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/39188/overview">Habibeh Khoshbouei</ext-link>, University of Florida, United&#x20;States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/157227/overview">Gaiqing Wang</ext-link>, The Third People&#x2019;s Hospital of Hainan Province, China</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>657033</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>01</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>05</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Tan, Fang and Gu.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Tan, Fang and Gu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Ferroptosis is a new form of programmed cell death characterized by intracellular iron-dependent accumulation of lipid peroxide and primarily associated with iron metabolism, glutathione-dependent pathway, and coenzyme Q<sub>10</sub>-dependent pathway. Recent studies demonstrate that ferroptosis is associated with central nervous system (CNS) diseases, such as stroke, Parkinson&#x2019;s disease, Alzheimer&#x2019;s disease, and Huntington&#x2019;s disease. This review summarizes the key regulatory mechanisms of ferroptosis and its role in CNS diseases. These updates may provide novel perspective for the development of therapeutical agents against CNS diseases.</p>
</abstract>
<kwd-group>
<kwd>ferroptosis</kwd>
<kwd>lipid metabolism</kwd>
<kwd>iron metabolism</kwd>
<kwd>glutathione peroxidase 4</kwd>
<kwd>coenzyme Q<sub>10</sub>
</kwd>
<kwd>central nervous system diseases</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>From organisms to cells, death is the common destiny of life. Conventional cell death removes damaged or harmful cells from organisms. Therefore, cell death is essential for the homeostasis of life. When cell death is over-activated, the body can suffer from many pathological conditions, such as nervous system diseases. Thus, understanding the process of cell death helps to intervene in cell death or survival and develop therapeutical solutions to treat associated diseases.</p>
<p>The major forms of cell deaths are divided into apoptosis, autophagy, and necrosis. Recently, morphological and biochemical criteria have been generated to articulate cell death and mechanisms. New cell death forms are discovered from time to time, such as pyroptosis (<xref ref-type="bibr" rid="B32">Fink and Cookson, 2005</xref>) and ferroptosis (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>).</p>
<p>Before the term &#x201c;ferroptosis&#x201d; was formally proposed, many scientists had observed this form of cell death (<xref ref-type="bibr" rid="B98">Wolpaw et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B101">Yagoda et&#x20;al., 2007</xref>). Without a systematic concept and detailed molecular knowledge, ferroptosis was attributed to the other existing forms of cell death and was considered to have no biological significance. In 2012, <xref ref-type="bibr" rid="B25">Dixon et&#x20;al. (2012)</xref> found that erastin, a small molecule inducer, could induce <italic>RAS</italic>-mutated tumor cell death by overwhelming lipid peroxidation that produced lipid reactive oxygen species (ROS, a class of highly reactive chemical molecules formed from the electron receptivity of O<sub>2</sub>). This cell death form depends on iron rather than other metals, and can be suppressed by iron chelator deferoxamine (DFO). Therefore, such cell death was termed as &#x201c;ferroptosis&#x201d; by Dixon and co-workers. Since then, ferroptosis has drawn a great attention. It was found vital to many pathophysiological conditions, such as nervous system diseases (<xref ref-type="bibr" rid="B24">Derry et&#x20;al., 2020</xref>), ischemia/reperfusion injury (<xref ref-type="bibr" rid="B41">Guan et&#x20;al., 2019</xref>), tumor (<xref ref-type="bibr" rid="B89">Shin et&#x20;al., 2020</xref>) and acute kidney injury (<xref ref-type="bibr" rid="B67">Ma et&#x20;al., 2020</xref>).</p>
<p>Based on the morphological, biochemical, and genetic characteristics, ferroptosis is distinct from other forms of cell death. Ferroptotic cells have smaller mitochondria with reduced crest, condensed membrane density and ruptured outer membranes (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>). The cells do not show rupture and blebbing on the plasma membranes, the features of apoptotic cells (<xref ref-type="bibr" rid="B99">Xie et&#x20;al., 2016</xref>). Using transmission electron microscopy, the ferroptotic cells can be distinguished from other forms of cell death. The main biochemical characteristic of ferroptosis is iron-dependent over-oxidation of polyunsaturated fatty acids (PUFAs)-containing phospholipids (PLs) on cell membranes (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>). Apoptosis has long benefited from the detection of the cleaved caspase-3. However, it is unclear what are the biomarkers (either transcriptional up-regulation or, post-translational modification of specific cell death effectors or, pore-forming proteins) required for the final execution of ferroptosis (<xref ref-type="bibr" rid="B48">Hirschhorn and Stockwell, 2019</xref>). Genetically, Dixon and his colleagues (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>) found that the expression of many genes changed in erastin-induced ferroptosis, including ribosomal protein L8 (<italic>RPL8</italic>), iron response element binding protein 2 (<italic>IREB2</italic>), ATP synthase F0 complex subunit C3 (<italic>ATP5G3</italic>), citrate synthase (<italic>CS</italic>), tetratricopeptide repeat domain 35 (<italic>TTC35</italic>) and acyl-CoA synthetase family member 2 (<italic>ACSF2</italic>). Meanwhile, many genes involved in the regulation of apoptosis and other non-apoptotic cell death were not altered. Subsequently, more genes are being found to be associated with ferroptosis, such as heat shock protein &#x3b2;-1 (<italic>HSPB1</italic>) (<xref ref-type="bibr" rid="B93">Sun et&#x20;al., 2015</xref>) and <italic>p53</italic> (<xref ref-type="bibr" rid="B52">Jiang et&#x20;al., 2015</xref>). Importantly, the expression of prostaglandin-endoperoxide synthase 2&#x20;<italic>(PTGS2)</italic> was found to be significantly upregulated in ferroptosis without changing ferroptosis process (<xref ref-type="bibr" rid="B103">Yang et&#x20;al., 2014</xref>). Thus, this gene expression is regarded as a biomarker of ferroptosis and utilized to distinguish ferroptosis from other forms of cell&#x20;death.</p>
<p>In this review, we summarize the mechanisms of modulation of ferroptosis and its role in central nervous system (CNS) diseases, and propose the possible strategies for finding new ferroptosis regulators.</p>
</sec>
<sec id="s2">
<title>The key regulatory mechanisms of ferroptosis</title>
<p>The essence of ferroptosis is intracellular excessive lipid peroxidation and the metabolic disorders of its product lipid hydroperoxides (LOOHs) (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). With iron as the catalyst, a large number of LOOHs are produced to destroy the intracellular redox balance and attack biological macromolecules, finally triggering cell death. These LOOHs are crucial factors to execute ferroptosis, and inhibiting their formation can suppress cell death. It is noteworthy that the lipid peroxidation and metabolic disorders of intracellular LOOHs are mainly related to iron metabolism (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>), glutathione (GSH)-dependent pathway (<xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>), and coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>)-dependent pathway (<xref ref-type="fig" rid="F1">Figure&#x20;1D</xref>). We will elaborate on these mechanisms&#x20;below.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The key regulatory mechanisms of ferroptosis. <bold>(A)</bold> Lipid metabolism. <bold>(B)</bold> Iron metabolism. <bold>(C)</bold> Glutathione-dependent pathway. <bold>(D)</bold> CoQ<sub>10</sub>-dependent pathway.</p>
</caption>
<graphic xlink:href="fphar-12-657033-g001.tif"/>
</fig>
<p>However, the mechanism that ultimately leads to ferroptotic cell death is still unclear, so further research is needed. There are two prevalent hypotheses: 1) Lipid peroxidation and ROS over-production destroy cell membrane integrity through damaging and perforating the cell membranes (<xref ref-type="bibr" rid="B1">Agmon et&#x20;al., 2018</xref>); 2) LOOHs are decomposed into toxic aldehydes, such as 4-hydroxy-2-nonenal (4-HNE) and malondialdehyde (MDA), which crosslink and dysfunction the proteins required for cell viability, resulting in cell death (<xref ref-type="bibr" rid="B108">Zhong and Yin, 2015</xref>; <xref ref-type="bibr" rid="B4">Angeli et&#x20;al., 2017</xref>).</p>
<sec id="s2-1">
<title>Lipid Metabolism</title>
<p>Compared with saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs), PUFAs are easier to be oxidized. This is because the double bond near the <italic>bis</italic>-allyl methylene group in PUFAs can weaken the hydrogen bonding energy of the methylene group, resulting in its sensitivity to dehydrogenation and subsequent oxygenation (<xref ref-type="bibr" rid="B31">Else, 2017</xref>). A recent study (<xref ref-type="bibr" rid="B53">Kagan et&#x20;al., 2017</xref>) demonstrated that, when containing the two types of PUFAs arachidonic acid (AA) and adrenic acid (AdA), the PLs especially phosphatidylethanolamines (PEs) on the cell membranes, are more susceptible to be oxidized. The over-oxidation can lead to ferroptosis eventually.</p>
<p>Before the initiation of lipid peroxidation, intracellular free AA and AdA need to be inserted into the PLs on the cell membranes. First, free AA and AdA are activated by acyl-CoA synthetase long-chain family member 4 (ACSL4) to form AA-CoA and AdA-CoA. Subsequently, they are inserted to PLs by esterification reaction under the catalysis of lysophosphatidylcholine acyltransferase 3 (LPCAT3) (<xref ref-type="bibr" rid="B68">Magtanong and Dixon, 2018</xref>). Consequently, the easily oxidized membrane PLs are synthesized, which are more likely to cause the lethal lipid peroxidation and ferroptosis. Therefore, the activities of these two enzymes are important to the cellular sensitivity to ferroptosis. The ACSL4 inhibitors thiazolidinediones (TZDs) include troglitazone (TRO), pioglitazone (PIO) and rosiglitazone (ROSI) (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>). They were reported to suppress ferroptosis in mouse embryonic fibroblasts (<xref ref-type="bibr" rid="B28">Doll et&#x20;al., 2017</xref>). Knockdown of <italic>Lpcat3</italic> could also make mouse lung epithelial cells and embryonic cells more resistant to ferroptosis (<xref ref-type="bibr" rid="B53">Kagan et&#x20;al., 2017</xref>). When ACSL4 or LPCAT3 are inhibited, the available substrates of lipid peroxidation are reduced and the lipid peroxidation is suppressed. ACSL4 and LPCAT3 are promising targets against ferroptosis or other peroxidation related diseases.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Regulators of ferroptosis. <bold>(A&#x2013;C)</bold> Inhibitors of ferroptosis. <bold>(D)</bold> Inducers of ferroptosis.</p>
</caption>
<graphic xlink:href="fphar-12-657033-g002.tif"/>
</fig>
<p>Lipoxygenases (LOXs) are iron-containing enzymes for cell membrane PLs oxidation, which are non-heme dioxygenases that catalyze the double oxygenation reaction of free and esterified PUFAs (<xref ref-type="bibr" rid="B13">Brash, 1999</xref>). Different subtypes of LOXs catalyze the dioxygenation of PUFAs at different positions. Baicalein, a naturel bioactive compound, was reported to inhibit ferroptosis by suppressing 12/15-LOX (<xref ref-type="bibr" rid="B62">Li et&#x20;al., 2019</xref>). The first step of LOXs catalysis is to abstract an unstable hydrogen from the <italic>bis</italic>-allyl position at a PUFA to form a pentadienyl radical (L&#x00B7;) (<xref ref-type="bibr" rid="B58">Kuhn et&#x20;al., 2015</xref>). This step can also be accomplished by an auto-oxidation reaction independent of LOXs. Highly reactive substances such as hydroxyl radicals (&#x00B7;OH), alkoxy groups (LO&#x00B7;) and hydroperoxyl radicals (HO<sub>2</sub>&#x00B7;) can take a hydrogen atom from the <italic>bis</italic>-allyl position of a PUFA (<xref ref-type="bibr" rid="B4">Angeli et&#x20;al., 2017</xref>). Subsequently, molecular oxygen is added to the carbon-centered radicals to yield a peroxy radical (LOO&#x00B7;). The LOO&#x00B7; can abstract a hydrogen atom from an adjacent PL to generate a LOOH and a new L&#x00B7;. As a result, this free radical chain reaction continues to propagate and generates more LOOHs (<xref ref-type="bibr" rid="B106">Yin et&#x20;al., 2011</xref>). Additionally, LOOHs can be oxidized by Fe<sup>2&#x2b;</sup>: the O-O bonds are broken and yield LO&#x00B7;. The LO&#x00B7; participates in the free radical chain reaction, destroys the adjacent PUFAs directly, and causes cell membrane damage and ferroptosis (<xref ref-type="bibr" rid="B38">Gaschler and Stockwell, 2017</xref>).</p>
<p>With Fe<sup>2&#x2b;</sup>, Fenton reaction converts hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to &#x00B7;OH radicals, which propagate free radical chain reactions (<xref ref-type="bibr" rid="B5">Ayala et&#x20;al., 2014</xref>). Radical trapping antioxidants (RTAs) provide electrons to neutralize free radicals (<xref ref-type="bibr" rid="B45">Hassannia et&#x20;al., 2019</xref>). This suppresses the propagation of lipid peroxidation and act as ferroptosis inhibitors. Such ferroptosis inhibitors include ferrostatin-1 (Fer-1) (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>), liproxstatin-1 (Lip-1) (<xref ref-type="bibr" rid="B33">Angeli et&#x20;al., 2014</xref>) and &#x3b1;-tocopherol (vitamin E) (<xref ref-type="bibr" rid="B54">Kajarabille and Latunde-Dada, 2019</xref>) (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>).</p>
</sec>
<sec id="s2-2">
<title>Iron Metabolism</title>
<p>The demand for iron is a defining characteristic of ferroptosis. Since Fe<sup>2&#x2b;</sup> catalyzes Fenton reaction, and also is an essential component of ROS-producing enzymes such as LOXs and NADPH oxidase, iron affects lipid peroxidation and cellular sensitivity to ferroptosis. Increasing the content of free Fe<sup>2&#x2b;</sup> in cells advances their sensitivity to ferroptosis. Conversely, iron chelators (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>) and other substances that can reduce the concentration of intracellular iron are able to inhibit ferroptosis. Under physiological conditions, cellular iron homeostasis is regulated through iron uptake, storage and export.</p>
<p>Transferrin (Tf)-mediated iron transport is the most important way of cellular iron uptake. It can transport Fe<sup>3&#x2b;</sup> from the place where Fe<sup>3&#x2b;</sup> is absorbed and stored to the iron-requiring site of the body. The Tf carrying Fe<sup>3&#x2b;</sup> is recognized by the transferrin receptor (TfR) on the cell membranes and endocytosed into the cells. Fe<sup>3&#x2b;</sup> is released from the Tf in the acidic environment of endosomes and reduced to Fe<sup>2&#x2b;</sup> by ferrous reductase. Afterwards, Fe<sup>2&#x2b;</sup> is transported to the cytoplasm through divalent metal transporter 1 (DMT1) on the endosomal membranes (<xref ref-type="bibr" rid="B51">Ji and Kosman, 2015</xref>). The free Fe<sup>2&#x2b;</sup> forms a labile iron pool (LIP) and plays its physiological or pathological roles. Inhibiting the iron uptake could reduce the level of LIP and suppress ferroptosis. For example, either immuno-depletion of Tf in serum or RNAi of <italic>TfR</italic> could significantly inhibit ferroptosis in mouse embryonic fibroblasts (<xref ref-type="bibr" rid="B36">Gao et&#x20;al., 2015</xref>).</p>
<p>The excess Fe<sup>2&#x2b;</sup> in the cells would be stored in ferritin (FT) to maintain the content of iron under normal physiological conditions. FT is a hollow globular protein shell composed of two types of subunits: ferritin heavy chain 1 (FTH1) and ferritin light chain (FTL) (<xref ref-type="bibr" rid="B44">Harrison and Arosio, 1996</xref>). Each FT can store about 4,500 Fe<sup>3&#x2b;</sup> in the form of Fe<sub>2</sub>O<sub>3</sub>&#x00B7;nH<sub>2</sub>O (<xref ref-type="bibr" rid="B50">Islam et&#x20;al., 1989</xref>). Oncogene-<italic>RAS</italic>-harboring cancer cells are more sensitive to ferroptosis, partly because <italic>RAS</italic> can down-regulate the expression of FTH1 and FTL, increasing intracellular LIP (<xref ref-type="bibr" rid="B105">Yang and Stockwell, 2008</xref>). Recent studies indicated that nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy played a crucial role in the regulation of iron levels. When available iron in cells is scarce, NCOA4 would recognize and bind to FTH1, and then recruit FT to autophagosomes. With the formation of autolysosomes, FT complexes enter lysosomes and are degraded, subsequently Fe<sup>3&#x2b;</sup> stored in these complexes would be released and supply the LIP. This process is also necessary for the execution of ferroptosis. Silencing the expression of NCOA4 by RNAi knockdown significantly inhibited ferritinophagy, thereby suppressing ferroptosis in mouse embryonic fibroblasts (<xref ref-type="bibr" rid="B35">Gao et&#x20;al., 2016</xref>).</p>
<p>In addition, excess intracellular Fe<sup>2&#x2b;</sup> can also be exported through ferroportin (FPN) on the cell membranes, which is the only known vertebrate iron efflux pump (<xref ref-type="bibr" rid="B12">Bogdan et&#x20;al., 2016</xref>). By regulating FPN, the content of intracellular Fe<sup>2&#x2b;</sup> can be changed, and ferroptosis can be mediated. It was reported that knockdown of <italic>Fpn</italic> in neuroblastoma cells could increase the accumulation of iron-dependent lipid ROS, and thereby accelerate erastin-induced ferroptosis (<xref ref-type="bibr" rid="B39">Geng et&#x20;al., 2018</xref>). Overexpression of <italic>FPN</italic> abolished the erastin-induced ferroptosis in ectopic endometrial stromal cells (<xref ref-type="bibr" rid="B63">Li et&#x20;al., 2021</xref>). In the brains of Alzheimer&#x27;s mouse model, genetic deletion of <italic>Fpn</italic> increased ferroptosis and then induced memory impairment, while restoring <italic>Fpn</italic> ameliorated ferroptosis and memory impairment (<xref ref-type="bibr" rid="B7">Bao et&#x20;al., 2021</xref>).</p>
</sec>
<sec id="s2-3">
<title>GSH-dependent Pathway</title>
<p>Glutathione peroxidase 4 (GPX4) is a selenium (Se)-containing enzyme, which plays a central role in the reduction of lipid ROS production. With consumption of two GSH molecules, GPX4 could reduce toxic LOOHs to non-toxic lipid alcohols (L-OHs). However, when GPX4 is deficient or inactive, LOOHs will accumulate to a high level, leading to catastrophic membrane damage. It is currently believed that inhibiting GPX4 by direct or indirect ways is the key to induce ferroptosis.</p>
<p>The ways to inhibit GPX4 directly mainly include covalently binding GPX4 and suppressing its expression. The compound Ras-selective lethal 3 (RSL3, <xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>), which can covalently bind to the selenocysteine (Sec) at the active site of GPX4 and inhibit its activity, is a highly effective ferroptosis inducer (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>). Knockout of <italic>Gpx4</italic> can promote ferroptosis in mouse embryonic fibroblasts, while overexpression of <italic>Gpx4</italic> made cells more resistant to RSL3-induced ferroptosis (<xref ref-type="bibr" rid="B103">Yang et&#x20;al., 2014</xref>).</p>
<p>Inhibiting GPX4 indirectly mainly involves inhibition of its cofactor GSH production. GSH is synthesized from three amino acids: glutamate (Glu), cysteine (Cys) and glycine (Gly). Among them, the amount of Cys is usually the least in cells, so it is considered to be the key factor limiting the <italic>de novo</italic> synthesis of GSH. Cys exists in its oxidized form cystine outside the cells. Through cystine/Glu antiporter (system <inline-formula id="inf1">
<mml:math id="m1">
<mml:mrow>
<mml:msubsup>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>&#x2212;</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>) on the cell membranes, an extracellular cystine is transported into cells, and meanwhile an intracellular Glu is exported. The system <inline-formula id="inf2">
<mml:math id="m2">
<mml:mrow>
<mml:msubsup>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>&#x2212;</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> is a disulfide-link heterodimer consisting of SLC7A11 (xCT) and regulatory subunit SLC3A2 (4F2hc and CD98hc) (<xref ref-type="bibr" rid="B86">Sato et&#x20;al., 1999</xref>). This transport process does not depend on ATP but is driven by the concentration difference of Glu or cystine on both sides of the membranes. Although Cys can be generated via the transsulfuration pathway in some cell types, in many other cell types, at least <italic>in&#x20;vitro</italic>, the import of cystine via system <inline-formula id="inf3">
<mml:math id="m3">
<mml:mrow>
<mml:msubsup>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>&#x2212;</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> is significant for maintaining the levels of Cys and GSH, and preventing ferroptosis (<xref ref-type="bibr" rid="B68">Magtanong and Dixon, 2018</xref>). When this transport is impaired, GSH will be depleted, making GPX4 unable to reduce LOOHs. For example, erastin (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>), a potent inducer of ferroptosis, is a specific inhibitor of the system <inline-formula id="inf4">
<mml:math id="m4">
<mml:mrow>
<mml:msubsup>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>&#x2212;</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>); the deletion of a system <inline-formula id="inf5">
<mml:math id="m5">
<mml:mrow>
<mml:msubsup>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>&#x2212;</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> subunit <italic>Slc7a11</italic> in mice induces ferroptosis and inhibits the growth of pancreatic ductal adenocarcinoma (<xref ref-type="bibr" rid="B6">Badgley et&#x20;al., 2020</xref>); high concentration of extracellular Glu inhibits the import of cystine and promotes ferroptosis, which is termed &#x201c;oxidative glutamate toxicity&#x201d; in neurons or neuronal-like cells (<xref ref-type="bibr" rid="B68">Magtanong and Dixon, 2018</xref>); cystine deprivation suppresses the growth of head and neck cancer by promoting ferroptosis (<xref ref-type="bibr" rid="B89">Shin et&#x20;al., 2020</xref>). Additionally, inhibiting the synthesis of GSH can also promote ferroptosis. The compound buthionine sulfoximine (BSO, <xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>) can induce ferroptosis in retinal pigment epithelium by inhibiting glutamate-cysteine ligase (GCL), a rate-limiting enzyme in <italic>de novo</italic> GSH synthesis (<xref ref-type="bibr" rid="B94">Sun et&#x20;al., 2018</xref>).</p>
</sec>
<sec id="s2-4">
<title>CoQ<sub>10</sub>-dependent Pathway</title>
<p>However, the responses of GPX4 inhibitors in different cell lines are not consistent (<xref ref-type="bibr" rid="B110">Zou et&#x20;al., 2019</xref>), indicating that there may be pathways independent of GPX4 to regulate ferroptosis.</p>
<p>Researchers have found that the mevalonate pathway could also affect ferroptosis. Isopentenyl pyrophosphate (IPP) is a direct metabolite of mevalonate, which can be used for Sec-tRNA prenylation, CoQ<sub>10</sub> synthesis and cholesterol biosynthesis (<xref ref-type="bibr" rid="B72">Moosmann and Behl, 2004</xref>). On the one hand, only the prenylated Sec-tRNA can carry Sec to GPX4, complete the synthesis of GPX4 (<xref ref-type="bibr" rid="B96">Warner et&#x20;al., 2000</xref>), and then inhibit ferroptosis (<xref ref-type="bibr" rid="B104">Yang and Stockwell, 2016</xref>); on the other hand, the reduced form of CoQ<sub>10</sub> (CoQ<sub>10</sub>-H<sub>2</sub>) is a potent lipophilic antioxidant, which can capture LOO&#x00B7; to prevent the spread of free radical chain reaction and inhibit the production of LOOHs, and meanwhile the CoQ<sub>10</sub>-H<sub>2</sub> is oxidized (<xref ref-type="bibr" rid="B10">Bentinger et&#x20;al., 2007</xref>). Therefore, inhibiting Sec-tRNA prenylation and CoQ<sub>10</sub> synthesis will disrupt GPX4 synthesis and CoQ<sub>10</sub>-H<sub>2</sub> antioxidant activity respectively, and eventually induce ferroptosis. For instance, FIN56 (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>) can activate squalene synthase (SQS), a key enzyme in cholesterol biosynthesis<sup>39</sup>, and then suppress Sec-tRNA prenylation and CoQ<sub>10</sub> synthesis, finally leading to ferroptosis in human fibrosarcoma HT1080 cells (<xref ref-type="bibr" rid="B45">Hassannia et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B88">Shimada et&#x20;al., 2016b</xref>). 3-Hydroxy-3-methyl glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR) is an important enzyme in the mevalonate pathway. Statins, as a type of inhibitors of HMGCR, can promote the lethality of FIN56 (<xref ref-type="bibr" rid="B88">Shimada et&#x20;al., 2016b</xref>).</p>
<p>Unless maintaining in the reduced state, the oxidized CoQ<sub>10</sub> is unable to inhibit the spread of LOOHs. In 2019, <xref ref-type="bibr" rid="B27">Doll et&#x20;al. (2019)</xref> and <xref ref-type="bibr" rid="B11">Bersuker et&#x20;al. (2019)</xref> conducted an overexpression screen and a synthetic lethal CRISPR-Cas9 knockout screen, respectively. Both groups revealed that ferroptosis suppressor protein 1 (FSP1) could suppress ferroptosis when knockout or inhibit GPX4. FSP1 is essentially a CoQ<sub>10</sub> oxidoreductase, which utilizes NAD(P)H to catalyze the reduction of CoQ<sub>10</sub>, maintaining the availability of CoQ<sub>10</sub>-H<sub>2</sub>. Bersuker et&#x20;al. (<xref ref-type="bibr" rid="B11">Bersuker et&#x20;al., 2019</xref>) found that the expression level of FSP1 was positively correlated with ferroptosis resistance in hundreds of cancer cell lines. Besides, in tumor xenograft mice model, the growth of <italic>GPX4</italic>
<sup>KO</sup>
<italic>FSP1</italic>
<sup>KO</sup> tumors was suppressed, while <italic>GPX4</italic>
<sup>KO</sup> tumors grew normally. Through screening nearly 10,000&#x20;drug-like compounds, Doll et&#x20;al. (<xref ref-type="bibr" rid="B27">Doll et&#x20;al., 2019</xref>) identified the first effective FSP1 inhibitor iFSP1 (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>). HT1080 and mouse Pfa1 treated with iFSP1 were much more sensitive to ferroptosis. In conclusion, by regulating the redox of CoQ<sub>10</sub>, FSP1 acts as an essential component of the non-mitochondrial CoQ<sub>10</sub> antioxidant system, as well as an enzyme catalytic system that is able to complement the loss of GPX4 in&#x20;cells.</p>
</sec>
<sec id="s2-5">
<title>Other Factors That Regulate Ferroptosis</title>
<p>Besides the above pathways, there are many other factors that are involved in the regulation of ferroptosis, including Se, NADPH, thioredoxin, transsulfuration pathway, glutaminolysis and nuclear factor erythroid 2-related factor 2 (NRF2) (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Other factors that regulate ferroptosis.</p>
</caption>
<graphic xlink:href="fphar-12-657033-g003.tif"/>
</fig>
<p>Se is currently recognized as an essential micronutrient beneficial to health. Its beneficial effects are mainly due to its incorporation into selenoprotein in the form of Sec (<xref ref-type="bibr" rid="B34">Friedmann Angeli and Conrad, 2018</xref>). Sec is similar to cysteine, in which sulfur is replaced by Se. As mentioned previously, Sec is an important component of GPX4. Therefore, Se influences cellular sensitivity to ferroptosis to some extent. It was reported that Se deprivation significantly increases oxidative stress in cells and their susceptibility to ferroptosis (<xref ref-type="bibr" rid="B19">Cardoso et&#x20;al., 2017</xref>). Moreover, <xref ref-type="bibr" rid="B49">Ingold et&#x20;al. (2018)</xref> generated mice with targeted mutation of the active site Sec to Cys of GPX4. They found the <italic>Gpx4</italic>
<sup>
<italic>cys/cys</italic>
</sup> mouse embryonic fibroblasts were extremely sensitive to peroxide-induced ferroptosis. In addition to directly participating in the synthesis of selenoproteins, Se may increase the resistance of cells to ferroptosis in indirect ways. A study showed that Se supplement could stimulate transcriptional adaptive program of cells to synthesize more antioxidant selenoproteins, including GPX4 and thioredoxin reductase 1 (TXNRD1), to block ferroptosis (<xref ref-type="bibr" rid="B2">Alim et&#x20;al., 2019</xref>).</p>
<p>NADPH can also modulate ferroptosis by indirectly affecting the activity of GPX4, due to that it is a vital reductant in the process of GSH production. The abundance of basal NADP(H) in cells is positively related to the resistance to ferroptosis. It was reported that knockdown of NAD<sup>&#x2b;</sup> kinase (NADK), an enzyme that uses NAD<sup>&#x2b;</sup> to synthesize NADP(H), was able to decrease NADP(H) levels in HT1080 cells and make them more susceptible to ferroptosis inducers (<xref ref-type="bibr" rid="B87">Shimada et&#x20;al., 2016a</xref>). In addition, NADPH oxidase (NOX) family, which is able to decrease the available level of intracellular NADPH, was found to be upregulated in several <italic>RAS</italic> mutant tumors (<xref ref-type="bibr" rid="B55">Kamata, 2009</xref>). Diphenylene iodonium (DPI), a NOX inhibitor, was found to prevent erastin-induced ferroptosis in <italic>KRAS</italic> mutant Calu-1 non-small cell lung cancer cells (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>).</p>
<p>Thioredoxin, a member of cellular antioxidant family (<xref ref-type="bibr" rid="B75">Nordberg and Arner, 2001</xref>), plays an important role in suppressing ferroptosis by maintaining and regulating the redox homeostasis. In a recent study, <xref ref-type="bibr" rid="B65">Llabani et&#x20;al. (2019)</xref> performed structural modification of the natural product pleuromutilin and synthesized a series of diverse compounds. Through phenotypic screen and biological evaluation, they discovered that the small molecule ferroptocide could induce lipid peroxidation and ferroptosis in some tumor cell lines. Subsequent studies identified ferroptocide is a covalent inhibitor of thioredoxin. This group also demonstrated that knockdown of thioredoxin led to massive generation of general and lipid ROS in HCT 116 colon cancer&#x20;cells.</p>
<p>As mentioned above, in some cell types, cysteine can be generated through the transsulfuration pathway rather than system <inline-formula id="inf6">
<mml:math id="m6">
<mml:mrow>
<mml:msubsup>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>&#x2212;</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>. When the intracellular cysteine is insufficient, methionine will act as a sulfur donor and undergo a series of reactions to produce cysteine, which can be used for the synthesis of GSH. Therefore, these cells are not sensitive to ferroptosis induced by inhibitors of system <inline-formula id="inf7">
<mml:math id="m7">
<mml:mrow>
<mml:msubsup>
<mml:mi mathvariant="normal">X</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>&#x2212;</mml:mo>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>. For example, <xref ref-type="bibr" rid="B47">Hayano et&#x20;al. (2016)</xref> found that activation of transsulfuration pathway in HT1080 cells could increase their resistance to erastin-induced ferroptosis. Inversely, <xref ref-type="bibr" rid="B95">Wang et&#x20;al. (2018)</xref> designed and synthesized a compound named CH004 as an inhibitor of cystathionine &#x3b2;-synthase, which catalyzes the first enzymatic reaction in the transsulfuration pathway. They found that compound CH004 triggered ferroptosis in hepatocellular carcinoma HepG2 cells and significantly suppressed tumor growth in a xenograft mice model bearing H22 mouse liver tumor&#x20;cells.</p>
<p>Glutaminolysis is the metabolism of intracellular glutamine, through which cells use glutamine as a carbon source for the mitochondrial tricarboxylic acid (TCA) cycle as well as a nitrogen source for the synthesis of certain necessary substances. <xref ref-type="bibr" rid="B36">Gao et&#x20;al. (2015)</xref> found that glutaminolysis was necessary for ferroptosis induced by cystine deprivation: either RNAi knockdown of glutamine influx receptor SLC1A5 or glutaminolysis inhibitor Compound 968 could inhibit cystine deprivation-induced ferroptosis. Mechanistically, the TCA cycle and electron transport chain in mitochondria drive this type of ferroptosis. Inhibition of glutaminolysis could suppress the TCA cycle, the hyperpolarization of mitochondrial membrane potential and the accumulation of lipid ROS, eventually inhibit ferroptosis (<xref ref-type="bibr" rid="B37">Gao et&#x20;al., 2019</xref>). This finding also confirmed the vital role of mitochondria in ferroptosis, which had been long-term controversial.</p>
<p>NRF2, a member of basic leucine zipper transcription factors, is a key regulator of cellular antioxidant response, because its target genes include some antioxidant proteins/enzymes genes. <xref ref-type="bibr" rid="B92">Sun et&#x20;al. (2016)</xref> revealed the p62-Kelch-like ECH-associated protein (Keap1)-NRF2 antioxidative signaling pathway involved in the ferroptosis resistance in hepatocellular carcinoma cells. They found that p62-mediated degradation of Keap1 could promote NRF2 activation. Thus, the genes NAD(P)H quinone oxidoreductase-1 (<italic>NQO1</italic>), heme oxygenase-1 (<italic>HO1</italic>) and <italic>FTH1</italic> regulated by NRF2 protected the cells from ferroptosis by modifying lipid peroxidation and iron metabolism. In addition, it was reported that the cells with higher expression levels of auxin response factor (ARF) were more susceptive to ferroptosis, as ARF could inhibit the ability of NRF2 to activate its target genes, including SLC7A11 (<xref ref-type="bibr" rid="B21">Chen et&#x20;al., 2017</xref>). Recently, a NRF2-Focadhesin (FOCAD)-focal adhesion kinase (FAK) signaling pathway was proposed. FOCAD-FAK signaling was able to make non-small-cell lung carcinoma cells more sensitive to cysteine deprivation-induced ferroptosis, while NRF2 could negatively regulate the pathway (<xref ref-type="bibr" rid="B64">Liu et&#x20;al., 2020</xref>). These findings underlined the role of NRF2 in ferroptosis.</p>
</sec>
</sec>
<sec id="s3">
<title>Ferroptosis and Central Nervous System Diseases</title>
<p>With the in-depth study of ferroptosis, its therapeutic potentials have also received widespread attention. It has been widely reported that ferroptosis inducers can potently kill tumor cells and inhibit tumor growth in mouse xenograft tumor models, which indicates that ferroptosis inducers are enormously potential in human cancer treatments (<xref ref-type="bibr" rid="B45">Hassannia et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B74">Mou et&#x20;al., 2019</xref>). For instance, <xref ref-type="bibr" rid="B46">Hassannia et&#x20;al. (2018)</xref> identified withaferin A as a natural ferroptosis inducer in neuroblastoma, which could inhibit the <italic>in vivo</italic> growth and recurrence rate of neuroblastoma xenografts. However, ferroptosis was also found to cause neuronal death in rat organotypic hippocampal slice culture (OHSC) models, showing the harmful pathological effect of ferroptosis (<xref ref-type="bibr" rid="B25">Dixon et&#x20;al., 2012</xref>). Moreover, the cells in CNS are more susceptible to ROS toxicity owing to their inherent more membranous fatty acids and less antioxidant enzymes, as well as higher oxidative metabolism (<xref ref-type="bibr" rid="B78">Olmez and Ozyurt, 2012</xref>). Increasing evidence (<xref ref-type="bibr" rid="B97">Weiland et&#x20;al., 2019</xref>) indicates that ferroptosis may be a driver in some CNS diseases caused by the dysfunction and cell death in CNS, such as stroke, Parkinson&#x27;s disease (PD), Alzheimer&#x27;s disease (AD), and Huntington&#x27;s disease (HD). <xref ref-type="table" rid="T1">Table&#x20;1</xref> shows reagents that modulate ferroptosis in animal models or patients of these CNS diseases. Thus ferroptosis inhibitors have exhibited great therapeutic potential for these CNS diseases. More and more efforts have been made to elucidate the role of ferroptosis in the pathogenesis of these diseases. We will elaborate on the relationship between ferroptosis and these CNS diseases&#x20;below.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Reagents that modulate ferroptosis in animal models or patients of CNS diseases.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">CNS diseases</th>
<th align="center">Reagents</th>
<th align="center">Functions</th>
<th align="center">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="3" align="left">Ischemic stroke</td>
<td align="left">Extract of Naotaifang</td>
<td align="left">Regulating TFR1/DMT1 and SCL7A11/GPX4 pathways</td>
<td align="left">
<xref ref-type="bibr" rid="B60">Lan et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">Carvacrol</td>
<td align="left">Increasing the expression of GPX4</td>
<td align="left">
<xref ref-type="bibr" rid="B41">Guan et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">Tat-inked SelP Peptide</td>
<td align="left">Upregulating the expression of GPX4</td>
<td align="left">
<xref ref-type="bibr" rid="B2">Alim et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Intracerebral hemorrhage stroke (ICH)</td>
<td align="left">DFO</td>
<td align="left">Chelating iron</td>
<td align="left">
<xref ref-type="bibr" rid="B77">Okauchi et&#x20;al. (2010)</xref>
</td>
</tr>
<tr>
<td align="left">Fer-1</td>
<td align="left">Trapping free radicals</td>
<td align="left">
<xref ref-type="bibr" rid="B61">Li et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">Parkinson&#x27;s disease (PD)</td>
<td align="left">FAC</td>
<td align="left">Upgrading ferritin levels</td>
<td align="left">
<xref ref-type="bibr" rid="B107">Zhang et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">Fer-1</td>
<td align="left">Trapping free radicals</td>
<td align="left">
<xref ref-type="bibr" rid="B26">Do Van et&#x20;al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">Deferiprone</td>
<td align="left">Chelating iron</td>
<td align="left">
<xref ref-type="bibr" rid="B70">Martin-Bastida et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Alzheimer&#x2019;s disease (AD)</td>
<td align="left">Lip-1</td>
<td align="left">Trapping free radicals</td>
<td align="left">
<xref ref-type="bibr" rid="B43">Hambright et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">Deferiprone</td>
<td align="left">Chelating iron</td>
<td align="left">
<xref ref-type="bibr" rid="B82">Rao et&#x20;al. (2020)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Huntington&#x2019;s disease (HD)</td>
<td align="left">DFO</td>
<td align="left">Chelating iron</td>
<td align="left">
<xref ref-type="bibr" rid="B22">Chen et&#x20;al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Fer-1 and its analogues</td>
<td align="left">Trapping free radicals</td>
<td align="left">
<xref ref-type="bibr" rid="B90">Skouta et&#x20;al. (2014)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s3-1">
<title>Stroke</title>
<p>In the United&#x20;States, about 795,000 people experience a new or recurrent stroke each year (<xref ref-type="bibr" rid="B9">Benjamin et&#x20;al., 2019</xref>). Of all strokes, 87% are ischemic stroke and 10% are intracerebral hemorrhage (ICH) stroke (<xref ref-type="bibr" rid="B9">Benjamin et&#x20;al., 2019</xref>). Stroke usually leads to irreparable brain damage and the patients have to suffer from severe sequelae, such as hemiplegia, language impairment and cognitive impairment.</p>
<p>Ischemic stroke is caused by occlusion or contraction of blood vessels that restricts blood supply to certain parts of the brain (<xref ref-type="bibr" rid="B8">Barthels and Das, 2020</xref>). Insufficient blood in the brain fails to provide enough oxygen and nutrients to neurons, leading to their activation of the ischemic cascade, which is followed by excitotoxicity, oxidative stress, blood&#x2013;brain barrier dysfunction, microvascular injury, hemostatic activation, post-ischemic inflammation and eventual cell death (<xref ref-type="bibr" rid="B40">Goossens and Hachimi-Idrissi, 2014</xref>). Before ferroptosis was identified, clinical studies had found that iron and oxidative stress could promote brain damage caused by ischemic stroke (<xref ref-type="bibr" rid="B17">Carbonell and Rama, 2007</xref>). Nowadays, increasing evidence reveals the relationship between ischemic stroke and ferroptosis. A recent study demonstrated that in acute ischemic stroke model of middle cerebral artery occlusion (MCAO) rats, neuronal ferroptosis was induced by the imbalance of iron metabolism and redox disorder (<xref ref-type="bibr" rid="B60">Lan et&#x20;al., 2020</xref>). While the extract of Naotaifang, a compound Chinese herbal medicine, could suppress ferroptosis through TFR1/DMT1 and SCL7A11/GPX4 pathways, and then played a neuroprotective role on MCAO rats (<xref ref-type="bibr" rid="B60">Lan et&#x20;al., 2020</xref>). This protective effect may be mediated by its active ingredients that can cross the blood-brain barrier and enter the brain tissue, but the blood brain permeability has not been examined. After cerebral ischemia, reperfusion is the most effective treatment. However, reperfusion will promote the production of ROS, increasing the damage and worsening the patients&#x2019; prognosis (<xref ref-type="bibr" rid="B78">Olmez and Ozyurt, 2012</xref>). Therefore, reducing brain ischemia/reperfusion injury is crucial in treating cerebral ischemia. <xref ref-type="bibr" rid="B41">Guan et&#x20;al. (2019)</xref> found that the natural product carvacrol could inhibit ferroptosis by increasing the expression of GPX4, thereby exerting its protective effects on cognitive dysfunction in gerbils exposed to ischemia/reperfusion, but the blood brain permeability of carvacrol has not been examined. Additionally, <xref ref-type="bibr" rid="B2">Alim et&#x20;al. (2019)</xref> created a Tat-linked SelP Peptide, which could greatly reduce the cerebral infarct volume caused by ischemia/reperfusion in mice. Mechanistically, this is because the Tat-linked SelP Peptide could block ferroptosis by driving transcriptional response to upregulate GPX4 in neurons.</p>
<p>Compared to ischemic stroke, ICH has a lower incidence (<xref ref-type="bibr" rid="B9">Benjamin et&#x20;al., 2019</xref>), but it leads to higher mortality and more severe disability (<xref ref-type="bibr" rid="B3">An et&#x20;al., 2017</xref>). ICH refers to bleeding into the brain due to rupture or leakage of blood vessels, leading to compression of brain tissue and neuronal damage. During this process, hemoglobin (Hb) and heme are released from the lysed erythrocytes. They are considered as neurotoxins because they can release iron and cause neuronal damage and death by enhancing the formation of ROS (<xref ref-type="bibr" rid="B100">Xiong et&#x20;al., 2014</xref>). The iron in dead cells can also be absorbed by surrounding cells, causing even more catastrophic consequences (<xref ref-type="bibr" rid="B100">Xiong et&#x20;al., 2014</xref>). The iron chelating agents DFO can effectively reduce ICH-induced neuronal damage in rats (<xref ref-type="bibr" rid="B77">Okauchi et&#x20;al., 2010</xref>), and the cell death caused by ICH has the characteristics of ferroptosis <italic>in vivo</italic> and <italic>in&#x20;vitro</italic> (<xref ref-type="bibr" rid="B109">Zille et&#x20;al., 2017</xref>), all verifying that ferroptosis is closely related to ICH brain damage. <xref ref-type="bibr" rid="B61">Li et&#x20;al. (2017)</xref> found that ferroptosis did occur in a mouse model of ICH and contributed to neuronal death. In addition, ferroptosis inhibitor Fer-1 can inhibit Hb-induced neuronal death in OHSCs.</p>
<p>In general, inhibiting ferroptosis can be a promising strategy for the prevention or treatments of stroke. However, no clinical trials that use ferroptosis inhibitors have been reported to treat stroke to&#x20;date.</p>
</sec>
<sec id="s3-2">
<title>PD</title>
<p>PD is the second most universal age-related neurodegenerative disease in the world (<xref ref-type="bibr" rid="B30">Elbaz et&#x20;al., 2016</xref>). The clinical manifestations include resting tremor, muscle rigidity, gait and posture disorders (<xref ref-type="bibr" rid="B16">Cacabelos, 2017</xref>), which cause great pain and inconvenience to the patients and their families. Parkinson&#x2019;s disease is characterized by the death of dopaminergic neurons, especially those in substantia nigra pars compacta (SNpc) and striatum (<xref ref-type="bibr" rid="B16">Cacabelos, 2017</xref>). The loss of dopaminergic neurons leads to insufficient secretion of dopamine, a pivotal neurotransmitter in the brain. Thus, the nerve conduction is blocked, leading to the symptoms of dyskinesia. Currently, dopamine-based therapies such as levodopa are used in clinic to relieve the motor symptoms in early PD (<xref ref-type="bibr" rid="B56">Katzenschlager and Lees, 2002</xref>). However, these treatments show severe side effects and have no improvement on the disease progression. Therefore, it is urgent to develop drugs that can slow or prevent the death of dopaminergic neurons in the&#x20;brain.</p>
<p>The iron accumulation found on SNpc is one of the characteristics of PD patients, suggesting the link between iron and PD (<xref ref-type="bibr" rid="B73">Moreau et&#x20;al., 2018</xref>). As a strong reducing agent, iron can not only cause ROS production in neurons, but also oxidize dopamine (<xref ref-type="bibr" rid="B42">Guiney et&#x20;al., 2017</xref>). Increasing data have indicated that ferroptosis is an important pathway for the cell death of dopaminergic neurons and the occurrence of PD. <xref ref-type="bibr" rid="B107">Zhang et&#x20;al. (2020)</xref> treated dopaminergic neurons MES23.5 cells with ferric ammonium citrate (FAC) to simulate the iron overload of PD, as FAC can upgrade ferritin levels in cells. They found ferroptosis occurred in the early stage of cell death, which was also detected in the PD mice. Furthermore, ferroptosis inhibitors also have a significant therapeutic effect on the PD mouse model. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, a well-established animal model of PD, <xref ref-type="bibr" rid="B26">Do Van et&#x20;al. (2016)</xref> confirmed that the ferroptosis inhibitor Fer-1 could inhibit the death of dopaminergic neurons. Inspiringly, the results of a phase II clinical trial for PD patients (clinical trial NCT01539837) showed that treatment with iron chelator deferiprone (30&#xa0;mg/kg) exhibited an improvement in motor symptoms and patients&#x2019; quality of life (<xref ref-type="bibr" rid="B70">Martin-Bastida et&#x20;al., 2017</xref>).</p>
</sec>
<sec id="s3-3">
<title>AD</title>
<p>AD is the most common type of irreversible dementia and a neurodegenerative disease that often occurs in the elderly. Its histological features are the accumulation of senile plaques composed of amyloid-&#x3b2; (A&#x3b2;) and neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau protein in the memory and cognition area of the brain (<xref ref-type="bibr" rid="B23">Citron, 2010</xref>). AD is caused by the degradation of memory and cognition neurons, which may be the result of the interaction of genes and environment. The manifestations include behavioral changes, progressive memory loss, delusions, hallucinations and degradation in fine motor skills. Therefore, the patients are unable to live independently, bringing a heavy burden to the patients&#x2019; families and the society.</p>
<p>Before the definition of ferroptosis, abnormal iron metabolism and lipid peroxidation had been found to participate in the pathogenesis of AD (<xref ref-type="bibr" rid="B76">Obulesu et&#x20;al., 2011</xref>). Evidence indicated that AD patients showed an excessive iron accumulation, which is more than 2&#x20;times the iron level observed in normal brains (<xref ref-type="bibr" rid="B66">Lovell et&#x20;al., 1998</xref>). Accumulation of iron can not only prompt the accumulation and/or aggregation of the A&#x3b2; and tau protein, but also induces the ROS production in the brain of AD (<xref ref-type="bibr" rid="B102">Yamamoto et&#x20;al., 2002</xref>). Oxidative stress is also reported to be an important pathological phenomenon that begins to appear early in the course of AD (<xref ref-type="bibr" rid="B85">Saito et&#x20;al., 2019</xref>). When redox balance in the brain is impaired, oxidative stress can cause serious damage leading to AD. Moreover, oxidative stress has been reported to exacerbate AD pathology and cognitive dysfunction (<xref ref-type="bibr" rid="B15">Butterfield, 1997</xref>). Besides, it was indicated that 12/15-LOX was upregulated in the brain of AD patients, which may be related to the oxidative imbalance of AD (<xref ref-type="bibr" rid="B81">Pratico et&#x20;al., 2004</xref>). Now increasing evidence implicates that ferroptosis may be involved in neuronal degeneration in AD. According to Morris water maze task, <italic>Gpx4</italic>
<sup>KO</sup> mice showed obvious defects in spatial learning and memory function, while ferroptosis inhibitor Lip-1 could ameliorate the neurodegeneration in these mice (<xref ref-type="bibr" rid="B43">Hambright et&#x20;al., 2017</xref>). Besides, a clinical measure on AD patients revealed that the level of GSH was reduced especially in the hippocampi (HP) and frontal cortices (FC), two vital brain regions related to the memory and cognition functions (<xref ref-type="bibr" rid="B69">Mandal et&#x20;al., 2015</xref>).</p>
<p>Therapeutically, iron chelator desferrioxamine has already been conducted a clinical trial in AD in 1991 (<xref ref-type="bibr" rid="B71">Crapper McLachlan et&#x20;al., 1991</xref>). A randomized, multi-center, double-blind Phase II trial using deferiprone for AD patients (clinical trial NCT03234686) is currently ongoing in Australia (<xref ref-type="bibr" rid="B82">Rao et&#x20;al., 2020</xref>). Moreover, as mentioned above, Se can increase the resistance of cells to ferroptosis. It was reported that Se deficiency in the human body was associated with an increased risk of AD (<xref ref-type="bibr" rid="B18">Cardoso et&#x20;al., 2014</xref>). However, in a phase&#x2161;clinical trial, though Se could be delivered into the CNS effectively by selenate, there were no significant effects on cognitive performance outcomes in AD patients. Therefore, the process of ferroptosis participating in AD needs further study, as AD may be the combination of many factors (<xref ref-type="bibr" rid="B20">Cardoso et&#x20;al., 2019</xref>).</p>
</sec>
<sec id="s3-4">
<title>HD</title>
<p>HD is an autosomal dominant neurodegenerative disease caused by the CAG repeat length mutation in the <italic>huntington</italic> gene (<xref ref-type="bibr" rid="B84">Ross and Tabrizi, 2011</xref>). It is characterized by highly selective and severe damage to the corpus striatum, resulting in dance-like movements, dystonia and progressive dementia. The mutant <italic>huntington</italic> may cause oxidative stress and neurotoxicity to the neurons in corpus striatum (<xref ref-type="bibr" rid="B79">Paul et&#x20;al., 2014</xref>), which ultimately results in neuronal dysfunction and neuronal cell death, leading to patients with motor and cognitive impairments. However, the pathological mechanism of HD is complicated and has not been fully elucidated&#x20;yet.</p>
<p>Some characteristics of ferroptosis have been observed in HD patients and experimental animal models, such as iron accumulation (<xref ref-type="bibr" rid="B29">Dominguez et&#x20;al., 2016</xref>), lipid oxidation (<xref ref-type="bibr" rid="B14">Brocardo et&#x20;al., 2016</xref>), oxidative stress (<xref ref-type="bibr" rid="B80">Pinho et&#x20;al., 2020</xref>) and GSH redox cycle dysregulation (<xref ref-type="bibr" rid="B83">Ribeiro et&#x20;al., 2012</xref>). For example, in R6/2 HD mouse brain, discrete puncta formed by iron accumulation was detected in the periplasmic cytoplasm of striated neurons by synchrotron X-ray fluorescence analysis (<xref ref-type="bibr" rid="B22">Chen et&#x20;al., 2013</xref>). HD patients showed higher plasma lipid peroxidation level and lower GSH level (<xref ref-type="bibr" rid="B57">Klepac et&#x20;al., 2007</xref>). Consistently, <xref ref-type="bibr" rid="B59">Kumar et&#x20;al. (2010)</xref> found decreased GSH and GSH-S-transferase in the striatum, cortex and hippocampus in 3-nitropropionic acid-induced HD mouse. These phenomena imply that ferroptosis may play an important role in the pathogenesis of&#x20;HD.</p>
<p>
<xref ref-type="bibr" rid="B91">Stack et&#x20;al. (2010)</xref> synthesized two triterpenoids derived from 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). They could reduce oxidative stress in the N171&#x2013;82Q transgenic mouse model of HD, and improved their rotorod performance and survival. Mechanically, these two triterpenoids activated the NRF2/antioxidant response element (ARE) pathway and upregulated NRF2/ARE induced genes in the brain and peripheral tissues. Therefore, compounds targeting the NRF2/ARE pathway show great promise for the treatment of HD. Some ferroptosis regulators have also been found to work in HD models. For instance, intraventricular delivery of the iron chelator DFO led to an improvement in the motor phenotype of R6/2 HD mice (<xref ref-type="bibr" rid="B22">Chen et&#x20;al., 2013</xref>). <xref ref-type="bibr" rid="B90">Skouta et&#x20;al. (2014)</xref> found that the ferroptosis inhibitor Fer-1 and its analogues could prevent cell death in the brain slice model of&#x20;HD.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Since ferroptosis was defined in 2012, the research on its mechanisms and clinical applications has been a hotspot. The currently known major regulatory mechanisms of ferroptosis involve intracellular lipid metabolism, iron metabolism, GSH-dependent pathway and CoQ<sub>10</sub>-dependent pathway as stated above. It is possible that certain novel regulators existing in ferroptosis have not been uncovered. And there are still many questions need to be solved regarding the mechanisms of ferroptosis and its relationship with diseases. For example, is there a final biomarker that executes the ferroptotic cell death and what is it? What other roles does mitochondrion play in ferroptosis except that TCA cycle promotes cystine deprivation-induced ferroptosis? Moreover, since much research on ferroptosis focuses on tumor cells, neuronal cells, kidney cells, and mouse embryonic fibroblasts, does ferroptosis occur in other cell types?</p>
<p>In addition to cancers, ferroptosis has also been reported to be associated with a variety of CNS diseases, and some ferroptosis inhibitors have achieved inspiring results in related animal models. Nonetheless, the role of ferroptosis in CNS diseases needs further elucidation, and currently there is no definitive evidence linking CNS diseases with ferroptosis in long-term animal model studies. Additionally, the existing small molecular regulators of ferroptosis are still limited, and have some disadvantages such as low stability and poor biocompatibility. Therefore, it is urgent to obtain potent ferroptosis inhibitors with good biocompatibility, strong stability and high safety by target-based or cell-based high-throughput screening, structural modification and other methods. The development of such compounds will be an important direction for the prevention and treatments of some human diseases such as CNS diseases.</p>
<p>In conclusion, the research on ferroptosis and its relationship with CNS diseases would be certainly potential for further understanding of the pathogenesis of these diseases and discovery of more effective therapeutic targets, although there are still many unsolved issues in the field. Since no effective therapeutic strategies toward CNS diseases, blockade of ferroptosis may be of value in the treatment of CNS diseases. Further insights into research related to ferroptosis are now likely to emerge rapidly.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Author Contributions</title>
<p>QT was responsible for original draft and visualization. YF was responsible for review and editing. QG was responsible for review and editing, supervision, and funding acquisition.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This work was supported in part by the Guangdong Basic and Applied Basic Research Foundation (2019A1515012138) and Guangdong Provincial Key Laboratory Construction Foundation (2017B030314030).</p>
</sec>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agmon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Solon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bassereau</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Modeling the Effects of Lipid Peroxidation during Ferroptosis on Membrane Properties</article-title>. <source>Sci. Rep.</source> <volume>8</volume>, <fpage>5155</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-23408-0</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alim</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Caulfield</surname>
<given-names>J.&#x20;T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Swarup</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Ivanova</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke</article-title>. <source>Cell</source> <volume>177</volume>, <fpage>1262</fpage>&#x2013;<lpage>1279</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.03.032</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>B.-W.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: an Update</article-title>. <source>J.&#x20;Stroke</source> <volume>19</volume>, <fpage>3</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.5853/jos.2016.00864</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angeli</surname>
<given-names>J.&#x20;P. F.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Ferroptosis Inhibition: Mechanisms and Opportunities</article-title>. <source>Trends Pharmacol. Sci.</source> <volume>38</volume>, <fpage>489</fpage>&#x2013;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2017.02.005</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayala</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Arg&#xfc;elles</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal</article-title>. <source>Oxidative Med. Cell Longevity</source> <volume>2014</volume>, <fpage>1</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1155/2014/360438</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badgley</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Maurer</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>DelGiorno</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Purohit</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cysteine Depletion Induces Pancreatic Tumor Ferroptosis in Mice</article-title>. <source>Science</source> <volume>368</volume>, <fpage>85</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaw9872</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname>
<given-names>W.-D.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.-T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Loss of Ferroportin Induces Memory Impairment by Promoting Ferroptosis in Alzheimer&#x27;s Disease</article-title>. <source>Cell Death Differ (in press)</source>. <pub-id pub-id-type="doi">10.1038/s41418-020-00685-9</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barthels</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Current Advances in Ischemic Stroke Research and Therapies</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Basis Dis.</source> <volume>1866</volume>, <fpage>165260</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2018.09.012</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benjamin</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Muntner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bittencourt</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>A. P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association</article-title>. <source>Circulation</source> <volume>139</volume>, <fpage>e56</fpage>. <pub-id pub-id-type="doi">10.1161/cir.0000000000000659</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bentinger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brismar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dallner</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The Antioxidant Role of Coenzyme Q</article-title>. <source>Mitochondrion</source> <volume>7</volume>, <fpage>S41</fpage>&#x2013;<lpage>S50</lpage>. <pub-id pub-id-type="doi">10.1016/j.mito.2007.02.006</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bersuker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hendricks</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Magtanong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>P. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The CoQ Oxidoreductase FSP1 Acts Parallel to GPX4 to Inhibit Ferroptosis</article-title>. <source>Nature</source> <volume>575</volume>, <fpage>688</fpage>&#x2013;<lpage>692</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1705-2</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogdan</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Miyazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsuji</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease</article-title>. <source>Trends Biochem. Sci.</source> <volume>41</volume>, <fpage>274</fpage>&#x2013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2015.11.012</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brash</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>274</volume>, <fpage>23679</fpage>&#x2013;<lpage>23682</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.34.23679</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brocardo</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>McGinnis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Christie</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Gil-Mohapel</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Time-course Analysis of Protein and Lipid Oxidation in the Brains of Yac128 Huntington&#x27;s Disease Transgenic Mice</article-title>. <source>Rejuvenation Res.</source> <volume>19</volume>, <fpage>140</fpage>&#x2013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1089/rej.2015.1736</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butterfield</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>&#x3b2;-Amyloid-Associated Free Radical Oxidative Stress and Neurotoxicity: Implications for Alzheimer&#x27;s Disease</article-title>. <source>Chem. Res. Toxicol.</source> <volume>10</volume>, <fpage>495</fpage>&#x2013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1021/tx960130e</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Parkinson&#x27;s Disease: from Pathogenesis to Pharmacogenomics</article-title>. <source>Ijms</source> <volume>18</volume>, <fpage>551</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18030551</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carbonell</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rama</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Iron, Oxidative Stress and Early Neurological Deterioration in Ischemic Stroke</article-title>. <source>Cmc</source> <volume>14</volume>, <fpage>857</fpage>&#x2013;<lpage>874</lpage>. <pub-id pub-id-type="doi">10.2174/092986707780363014</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardoso</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Bandeira</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Jacob-Filho</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Franciscato Cozzolino</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Selenium Status in Elderly: Relation to Cognitive Decline</article-title>. <source>J.&#x20;Trace Elem. Med. Bio.</source> <volume>28</volume>, <fpage>422</fpage>&#x2013;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtemb.2014.08.009</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardoso</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Glutathione Peroxidase 4: a New Player in Neurodegeneration?</article-title>. <source>Mol. Psychiatry</source> <volume>22</volume>, <fpage>328</fpage>&#x2013;<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.196</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardoso</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Malpas</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Vivash</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Genc</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saling</surname>
<given-names>M. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Supranutritional Sodium Selenate Supplementation Delivers Selenium to the central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer&#x27;s Disease</article-title>. <source>Neurotherapeutics</source> <volume>16</volume>, <fpage>192</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-018-0662-z</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tavana</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Erber</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Baer</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>NRF2 Is a Major Target of ARF in P53-independent Tumor Suppression</article-title>. <source>Mol. Cel</source> <volume>68</volume>, <fpage>224</fpage>&#x2013;<lpage>232 e4</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2017.09.009</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Duce</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>L. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Iron Accumulates in Huntington&#x27;s Disease Neurons: protection by Deferoxamine</article-title>. <source>Plos One</source> <volume>8</volume>, <fpage>e77023</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0077023</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Citron</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Alzheimer&#x27;s Disease: Strategies for Disease Modification</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>9</volume>, <fpage>387</fpage>&#x2013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2896</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derry</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Kayed</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tour</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>A.-L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Revisiting the Intersection of Amyloid, Pathologically Modified Tau and Iron in Alzheimer&#x27;s Disease from a Ferroptosis Perspective</article-title>. <source>Prog. Neurobiol.</source> <volume>184</volume>, <fpage>101716</fpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2019.101716</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Lemberg</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Lamprecht</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zaitsev</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Gleason</surname>
<given-names>C. E.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Ferroptosis: an Iron-dependent Form of Nonapoptotic Cell Death</article-title>. <source>Cell</source> <volume>149</volume>, <fpage>1060</fpage>&#x2013;<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do Van</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gouel</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jonneaux</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Timmerman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gel&#xe9;</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>P&#xe9;trault</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Ferroptosis, a Newly Characterized Form of Cell Death in Parkinson&#x27;s Disease that Is Regulated by PKC</article-title>. <source>Neurobiol. Dis.</source> <volume>94</volume>, <fpage>169</fpage>&#x2013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2016.05.011</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>F. P.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aldrovandi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Ingold</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>FSP1 Is a Glutathione-independent Ferroptosis Suppressor</article-title>. <source>Nature</source> <volume>575</volume>, <fpage>693</fpage>&#x2013;<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1707-0</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Proneth</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tyurina</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Panzilius</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ingold</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>ACSL4 Dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition</article-title>. <source>Nat. Chem. Biol.</source> <volume>13</volume>, <fpage>91</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2239</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dom&#xed;nguez</surname>
<given-names>J.&#x20;F.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Poudel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Stout</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Churchyard</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chua</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Iron Accumulation in the Basal Ganglia in Huntington&#x27;s Disease: Cross-Sectional Data from the IMAGE-HD Study</article-title>. <source>J.&#x20;Neurol. Neurosurg. Psychiatry</source> <volume>87</volume>, <fpage>545</fpage>&#x2013;<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp-2014-310183</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbaz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carcaillon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kab</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moisan</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Epidemiology of Parkinson&#x27;s Disease</article-title>. <source>Revue Neurologique</source> <volume>172</volume>, <fpage>14</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurol.2015.09.012</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Else</surname>
<given-names>P. L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Membrane Peroxidation in Vertebrates: Potential Role in Metabolism and Growth</article-title>. <source>Eur. J.&#x20;Lipid Sci. Technol.</source> <volume>119</volume>, <fpage>1600319</fpage>. <pub-id pub-id-type="doi">10.1002/ejlt.201600319</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Cookson</surname>
<given-names>B. T.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells</article-title>. <source>Iai</source> <volume>73</volume>, <fpage>1907</fpage>&#x2013;<lpage>1916</lpage>. <pub-id pub-id-type="doi">10.1128/iai.73.4.1907-1916.2005</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedmann Angeli</surname>
<given-names>J.&#x20;P.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Proneth</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tyurina</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Tyurin</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>V. J.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Inactivation of the Ferroptosis Regulator Gpx4 Triggers Acute Renal Failure in Mice</article-title>. <source>Nat. Cel Biol.</source> <volume>16</volume>, <fpage>1180</fpage>&#x2013;<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1038/ncb3064</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedmann Angeli</surname>
<given-names>J.&#x20;P.</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Selenium and GPX4, a Vital Symbiosis</article-title>. <source>Free Radic. Biol. Med.</source> <volume>127</volume>, <fpage>153</fpage>&#x2013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.03.001</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Monian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Ferroptosis Is an Autophagic Cell Death Process</article-title>. <source>Cell Res</source> <volume>26</volume>, <fpage>1021</fpage>&#x2013;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2016.95</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Monian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Quadri</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ramasamy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Glutaminolysis and Transferrin Regulate Ferroptosis</article-title>. <source>Mol. Cel</source> <volume>59</volume>, <fpage>298</fpage>&#x2013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2015.06.011</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Minikes</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Monian</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>C. B.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Role of Mitochondria in Ferroptosis</article-title>. <source>Mol. Cel</source> <volume>73</volume>, <fpage>354</fpage>&#x2013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2018.10.042</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaschler</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Lipid Peroxidation in Cell Death</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>482</volume>, <fpage>419</fpage>&#x2013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.10.086</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geng</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Xua</surname>
<given-names>W. L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Knockdown of Ferroportin Accelerates Erastin-Induced Ferroptosis in Neuroblastoma Cells</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source> <volume>22</volume>, <fpage>3826</fpage>&#x2013;<lpage>3836</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_201806_15267</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goossens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hachimi-Idrissi</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after an Ischemic Cerebral Insult</article-title>. <source>Cn</source> <volume>12</volume>, <fpage>399</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.2174/1570159x12666140424233036</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ba</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The Neuroprotective Effects of Carvacrol on Ischemia/reperfusion-Induced Hippocampal Neuronal Impairment by Ferroptosis Mitigation</article-title>. <source>Life Sci.</source> <volume>235</volume>, <fpage>116795</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2019.116795</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guiney</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Adlard</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Finkelstein</surname>
<given-names>D. I.</given-names>
</name>
<name>
<surname>Ayton</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Ferroptosis and Cell Death Mechanisms in Parkinson&#x27;s Disease</article-title>. <source>Neurochem. Int.</source> <volume>104</volume>, <fpage>34</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2017.01.004</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hambright</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Ablation of Ferroptosis Regulator Glutathione Peroxidase 4 in Forebrain Neurons Promotes Cognitive Impairment and Neurodegeneration</article-title>. <source>Redox Biol.</source> <volume>12</volume>, <fpage>8</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2017.01.021</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Arosio</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>The Ferritins: Molecular Properties, Iron Storage Function and Cellular Regulation</article-title>. <source>Biochim. Biophys. Acta (Bba) - Bioenerg.</source> <volume>1275</volume>, <fpage>161</fpage>&#x2013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/0005-2728(96)00022-9</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassannia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Vandenabeele</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vanden Berghe</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Targeting Ferroptosis to Iron Out Cancer</article-title>. <source>Cancer Cell</source> <volume>35</volume>, <fpage>830</fpage>&#x2013;<lpage>849</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2019.04.002</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassannia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wiernicki</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ingold</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Van Herck</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tyurina</surname>
<given-names>Y. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Nano-targeted Induction of Dual Ferroptotic Mechanisms Eradicates High-Risk Neuroblastoma</article-title>. <source>J.&#x20;Clin. Invest.</source> <volume>128</volume>, <fpage>3341</fpage>&#x2013;<lpage>3355</lpage>. <pub-id pub-id-type="doi">10.1172/jci99032</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Corn</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Pagano</surname>
<given-names>N. C.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Loss of Cysteinyl-tRNA Synthetase (CARS) Induces the Transsulfuration Pathway and Inhibits Ferroptosis Induced by Cystine Deprivation</article-title>. <source>Cel Death Differ</source> <volume>23</volume>, <fpage>270</fpage>&#x2013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2015.93</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirschhorn</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Development of the Concept of Ferroptosis</article-title>. <source>Free Radic. Biol. Med.</source> <volume>133</volume>, <fpage>130</fpage>&#x2013;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.09.043</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingold</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Berndt</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poschmann</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Buday</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis</article-title>. <source>Cell</source> <volume>172</volume>, <fpage>409</fpage>&#x2013;<lpage>422.e21</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.11.048</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Islam</surname>
<given-names>Q. T.</given-names>
</name>
<name>
<surname>Sayers</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Theil</surname>
<given-names>E. C.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Studies of Temperature Dependence of Iron Environment in an Undecairon(III) Oxo-Hydroxo Aggregate Compound Compared to Horse Spleen Ferritin</article-title>. <source>Physica B: Condensed Matter</source> <volume>158</volume>, <fpage>99</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/0921-4526(89)90213-5</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kosman</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Molecular Mechanisms of Non-transferrin-bound and Transferring-Bound Iron Uptake in Primary Hippocampal Neurons</article-title>. <source>J.&#x20;Neurochem.</source> <volume>133</volume>, <fpage>668</fpage>&#x2013;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13040</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.-J.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hibshoosh</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Ferroptosis as a P53-Mediated Activity during Tumour Suppression</article-title>. <source>Nature</source> <volume>520</volume>, <fpage>57</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/nature14344</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kagan</surname>
<given-names>V. E.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Angeli</surname>
<given-names>J.&#x20;P. F.</given-names>
</name>
<name>
<surname>Doll</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Croix</surname>
<given-names>C. S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Oxidized Arachidonic and Adrenic PEs Navigate Cells to Ferroptosis</article-title>. <source>Nat. Chem. Biol.</source> <volume>13</volume>, <fpage>81</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2238</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kajarabille</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Latunde-Dada</surname>
<given-names>G. O.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Programmed Cell-Death by Ferroptosis: Antioxidants as Mitigators</article-title>. <source>Ijms</source> <volume>20</volume>, <fpage>4968</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20194968</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamata</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Roles of Nox1 and Other Nox Isoforms in Cancer Development</article-title>. <source>Cancer Sci.</source> <volume>100</volume>, <fpage>1382</fpage>&#x2013;<lpage>1388</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01207.x</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katzenschlager</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Treatment of Parkinson&#x27;s Disease: Levodopa as the First Choice</article-title>. <source>J.&#x20;Neurol.</source> <volume>249</volume> (<issue>Suppl. 2</issue>), <fpage>II19</fpage>-<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-002-1204-4</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klepac</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Relja</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Klepac</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>He&#x107;imovi&#x107;</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Babi&#x107;</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Trkulja</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Oxidative Stress Parameters in Plasma of Huntington&#x27;s Disease Patients, Asymptomatic Huntington&#x27;s Disease Gene Carriers and Healthy Subjects</article-title>. <source>J.&#x20;Neurol.</source> <volume>254</volume>, <fpage>1676</fpage>&#x2013;<lpage>1683</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-007-0611-y</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhn</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Banthiya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Leyen</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Mammalian Lipoxygenases and Their Biological Relevance</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Cel Biol. Lipids</source> <volume>1851</volume>, <fpage>308</fpage>&#x2013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2014.10.002</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kalonia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Nitric Oxide Mechanism in the Protective Effect of Antidepressants against 3-nitropropionic Acid-Induced Cognitive Deficit, Glutathione and Mitochondrial Alterations in Animal Model of Huntington&#x27;s Disease</article-title>. <source>Behav. Pharmacol.</source> <volume>21</volume>, <fpage>217</fpage>&#x2013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1097/fbp.0b013e32833a5bf4</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>S.-W.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.-L.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Extract of Naotaifang, a Compound Chinese Herbal Medicine, Protects Neuron Ferroptosis Induced by Acute Cerebral Ischemia in Rats</article-title>. <source>J.&#x20;Integr. Med.</source> <volume>18</volume>, <fpage>344</fpage>&#x2013;<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1016/j.joim.2020.01.008</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Durham</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Inhibition of Neuronal Ferroptosis Protects Hemorrhagic Brain</article-title>. <source>JCI Insight</source> <volume>2</volume>, <fpage>e90777</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.90777</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.-Q.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>J.-N.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.-Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.-H.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>W.-L.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Baicalein Exerts Neuroprotective Effects in FeCl3-Induced Posttraumatic Epileptic Seizures via Suppressing Ferroptosis</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>38</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.00638</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Erastin Induces Ferroptosis via Ferroportin-Mediated Iron Accumulation in Endometriosis</article-title>. <source>Hum. Reprod.</source> <volume>36</volume>, <fpage>951</fpage>&#x2013;<lpage>964</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/deaa363</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>NRF2 Regulates the Sensitivity of Human NSCLC Cells to Cystine Deprivation-Induced Ferroptosis via FOCAD-FAK Signaling Pathway</article-title>. <source>Redox Biol.</source> <volume>37</volume>, <fpage>101702</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2020.101702</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Llabani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hicklin</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Motika</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Weerapana</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Diverse Compounds from Pleuromutilin lead to a Thioredoxin Inhibitor and Inducer of Ferroptosis</article-title>. <source>Nat. Chem.</source> <volume>11</volume>, <fpage>521</fpage>&#x2013;<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1038/s41557-019-0261-6</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lovell</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Teesdale</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Markesbery</surname>
<given-names>W. R.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Copper, Iron and Zinc in Alzheimer&#x27;s Disease Senile Plaques</article-title>. <source>J.&#x20;Neurol. Sci.</source> <volume>158</volume>, <fpage>47</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/s0022-510x(98)00092-6</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Inhibition of Ferroptosis Attenuates Acute Kidney Injury in Rats with Severe Acute Pancreatitis</article-title>. <source>Dig. Dis. Sci.</source> <volume>66</volume>, <fpage>483</fpage>&#x2013;<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-020-06225-2</pub-id> </citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magtanong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Ferroptosis and Brain Injury</article-title>. <source>Dev. Neurosci.</source> <volume>40</volume>, <fpage>382</fpage>&#x2013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1159/000496922</pub-id> </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandal</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Saharan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Murari</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Brain Glutathione Levels - a Novel Biomarker for Mild Cognitive Impairment and Alzheimer&#x27;s Disease</article-title>. <source>Biol. Psychiatry</source> <volume>78</volume>, <fpage>702</fpage>&#x2013;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.04.005</pub-id> </citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin-Bastida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Newbould</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Piccini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kabba</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Brain Iron Chelation by Deferiprone in a Phase 2 Randomised Double-Blinded Placebo Controlled Clinical Trial in Parkinson&#x27;s Disease</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>1398</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-01402-2</pub-id> </citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mclachlan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Kruck</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Kalow</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>1991</year>). <article-title>Intramuscular Desferrioxamine in Patients with Alzheimer&#x27;s Disease</article-title>. <source>The Lancet</source> <volume>337</volume>, <fpage>1304</fpage>&#x2013;<lpage>1308</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(91)92978-b</pub-id> </citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moosmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Behl</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Selenoproteins, Cholesterol-Lowering Drugs, and the Consequences Revisiting of the Mevalonate Pathway</article-title>. <source>Trends Cardiovasc. Med.</source> <volume>14</volume>, <fpage>273</fpage>&#x2013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcm.2004.08.003</pub-id> </citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreau</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duce</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Rascol</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Devedjian</surname>
<given-names>J.-C.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dexter</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Iron as a Therapeutic Target for Parkinson&#x27;s Disease</article-title>. <source>Mov Disord.</source> <volume>33</volume>, <fpage>568</fpage>&#x2013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1002/mds.27275</pub-id> </citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Ferroptosis, a New Form of Cell Death: Opportunities and Challenges in Cancer</article-title>. <source>J.&#x20;Hematol. Oncol.</source> <volume>12</volume>, <fpage>34</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-019-0720-y</pub-id> </citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arn&#xe9;r</surname>
<given-names>E. S. J.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Reactive Oxygen Species, Antioxidants, and the Mammalian Thioredoxin System1 1This Review Is Based on the Licentiate Thesis "Thioredoxin Reductase-Interactions with the Redox Active Compounds 1-Chloro-2,4-Dinitrobenzene and Lipoic Acid" by Jonas Nordberg, 2001, Karolinska Institute, Stockholm, ISBN 91-631-1064-4</article-title>. <source>Free Radic. Biol. Med.</source> <volume>31</volume> (<issue>11</issue>), <fpage>1287</fpage>&#x2013;<lpage>1312</lpage>. <pub-id pub-id-type="doi">10.1016/s0891-5849(01)00724-9</pub-id> </citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obulesu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Venu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Somashekhar</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Lipid Peroxidation in Alzheimer&#x27;s Disease: Emphasis on Metal-Mediated Neurotoxicity</article-title>. <source>Acta Neurol. Scand.</source> <volume>124</volume>, <fpage>295</fpage>&#x2013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0404.2010.01483.x</pub-id> </citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okauchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Keep</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Morgenstern</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Schallert</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Deferoxamine Treatment for Intracerebral Hemorrhage in Aged Rats</article-title>. <source>Stroke</source> <volume>41</volume>, <fpage>375</fpage>&#x2013;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1161/strokeaha.109.569830</pub-id> </citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olmez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ozyurt</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Reactive Oxygen Species and Ischemic Cerebrovascular Disease</article-title>. <source>Neurochem. Int.</source> <volume>60</volume>, <fpage>208</fpage>&#x2013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2011.11.009</pub-id> </citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paul</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Sbodio</surname>
<given-names>J.&#x20;I.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vandiver</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>J.&#x20;Y.</given-names>
</name>
<name>
<surname>Snowman</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Cystathionine &#x3b3;-lyase Deficiency Mediates Neurodegeneration in Huntington&#x27;s Disease</article-title>. <source>Nature</source> <volume>509</volume>, <fpage>96</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1038/nature13136</pub-id> </citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinho</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Canas</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>P. I.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>J.&#x20;M. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Interplay between Redox Signalling and Proteostasis in Neurodegeneration: <italic>In Vivo</italic> Effects of a Mitochondria-Targeted Antioxidant in Huntington&#x27;s Disease Mice</article-title>. <source>Free Radic. Biol. Med.</source> <volume>146</volume>, <fpage>372</fpage>&#x2013;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.11.021</pub-id> </citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratic&#xf2;</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhukareva</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Uryu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Funk</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>12/15-Lipoxygenase Is Increased in Alzheimer&#x27;s Disease</article-title>. <source>Am. J.&#x20;Pathol.</source> <volume>164</volume>, <fpage>1655</fpage>&#x2013;<lpage>1662</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9440(10)63724-8</pub-id> </citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Portbury</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Lago</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Adlard</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy1</article-title>. <source>Jad</source> <volume>77</volume>, <fpage>753</fpage>&#x2013;<lpage>771</lpage>. <pub-id pub-id-type="doi">10.3233/jad-200551</pub-id> </citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribeiro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rosenstock</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Cunha-Oliveira</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>I. L.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Rego</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Glutathione Redox Cycle Dysregulation in Huntington&#x27;s Disease Knock-In Striatal Cells</article-title>. <source>Free Radic. Biol. Med.</source> <volume>53</volume>, <fpage>1857</fpage>&#x2013;<lpage>1867</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.09.004</pub-id> </citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Tabrizi</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Huntington&#x27;s Disease: from Molecular Pathogenesis to Clinical Treatment</article-title>. <source>Lancet Neurol.</source> <volume>10</volume>, <fpage>83</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/s1474-4422(10)70245-3</pub-id> </citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hisahara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iwahara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Emoto</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Yokokawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Early Administration of Galantamine from Preplaque Phase Suppresses Oxidative Stress and Improves Cognitive Behavior in APPswe/PS1dE9 Mouse Model of Alzheimer&#x27;s Disease</article-title>. <source>Free Radic. Biol. Med.</source> <volume>145</volume>, <fpage>20</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.09.014</pub-id> </citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tamba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bannai</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Cloning and Expression of a Plasma Membrane Cystine/glutamate Exchange Transporter Composed of Two Distinct Proteins</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>274</volume>, <fpage>11455</fpage>&#x2013;<lpage>11458</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.17.11455</pub-id> </citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pagano</surname>
<given-names>N. C.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2016a</year>). <article-title>Cell-line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity</article-title>. <source>Cel Chem. Biol.</source> <volume>23</volume>, <fpage>225</fpage>&#x2013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2015.11.016</pub-id> </citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Hayano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
<etal/>
</person-group> (<year>2016b</year>). <article-title>Global Survey of Cell Death Mechanisms Reveals Metabolic Regulation of Ferroptosis</article-title>. <source>Nat. Chem. Biol.</source> <volume>12</volume>, <fpage>497</fpage>&#x2013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.2079</pub-id> </citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>J.-L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Dihydrolipoamide Dehydrogenase Regulates Cystine Deprivation-Induced Ferroptosis in Head and Neck Cancer</article-title>. <source>Redox Biol.</source> <volume>30</volume>, <fpage>101418</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2019.101418</pub-id> </citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Orman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models</article-title>. <source>J.&#x20;Am. Chem. Soc.</source> <volume>136</volume>, <fpage>4551</fpage>&#x2013;<lpage>4556</lpage>. <pub-id pub-id-type="doi">10.1021/ja411006a</pub-id> </citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stack</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wille</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Calingasan</surname>
<given-names>N. Y.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liby</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Triterpenoids CDDO-Ethyl Amide and CDDO-Trifluoroethyl Amide Improve the Behavioral Phenotype and Brain Pathology in a Transgenic Mouse Model of Huntington&#x27;s Disease</article-title>. <source>Free Radic. Biol. Med.</source> <volume>49</volume>, <fpage>147</fpage>&#x2013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.03.017</pub-id> </citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Activation of the P62-Keap1-NRF2 Pathway Protects against Ferroptosis in Hepatocellular Carcinoma Cells</article-title>. <source>Hepatology</source> <volume>63</volume>, <fpage>173</fpage>&#x2013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28251</pub-id> </citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>HSPB1 as a Novel Regulator of Ferroptotic Cancer Cell Death</article-title>. <source>Oncogene</source> <volume>34</volume>, <fpage>5617</fpage>&#x2013;<lpage>5625</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2015.32</pub-id> </citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Glutathione Depletion Induces Ferroptosis, Autophagy, and Premature Cell Senescence in Retinal Pigment Epithelial Cells</article-title>. <source>Cell Death Dis</source> <volume>9</volume>, <fpage>753</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-018-0794-4</pub-id> </citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A Pharmacological Probe Identifies Cystathionine &#x3b2;-synthase as a New Negative Regulator for Ferroptosis</article-title>. <source>Cel Death Dis</source> <volume>9</volume>, <fpage>1005</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-018-1063-2</pub-id> </citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warner</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Moustafa</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Hatfield</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Faust</surname>
<given-names>J.&#x20;R.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Inhibition of Selenoprotein Synthesis by Selenocysteine tRNA[Ser]Sec Lacking Isopentenyladenosine</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>275</volume>, <fpage>28110</fpage>&#x2013;<lpage>28119</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M001280200</pub-id> </citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiland</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Ferroptosis and its Role in Diverse Brain Diseases</article-title>. <source>Mol. Neurobiol.</source> <volume>56</volume>, <fpage>4880</fpage>&#x2013;<lpage>4893</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-018-1403-3</pub-id> </citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolpaw</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Welsch</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Akavia</surname>
<given-names>U. D.</given-names>
</name>
<name>
<surname>Pe&#x27;er</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Modulatory Profiling Identifies Mechanisms of Small Molecule-Induced Cell Death</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>108</volume>, <fpage>E771</fpage>&#x2013;<lpage>E780</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1106149108</pub-id> </citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Ferroptosis: Process and Function</article-title>. <source>Cel Death Differ</source> <volume>23</volume>, <fpage>369</fpage>&#x2013;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2015.158</pub-id> </citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>Z.-M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.-W.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Iron and Intracerebral Hemorrhage: from Mechanism to Translation</article-title>. <source>Transl. Stroke Res.</source> <volume>5</volume>, <fpage>429</fpage>&#x2013;<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1007/s12975-013-0317-7</pub-id> </citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yagoda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>von Rechenberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zaganjor</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Fridman</surname>
<given-names>D. J.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Ras-raf-mek-dependent Oxidative Cell Death Involving Voltage-dependent Anion Channels</article-title>. <source>Nature</source> <volume>447</volume>, <fpage>865</fpage>&#x2013;<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1038/nature05859</pub-id> </citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>R.-W.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Naiki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yoshimasu</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Iron (III) Induces Aggregation of Hyperphosphorylated &#x3c4; and its Reduction to Iron (II) Reverses the Aggregation: Implications in the Formation of Neurofibrillary Tangles of Alzheimer&#x27;s Disease</article-title>. <source>J.&#x20;Neurochem.</source> <volume>82</volume>, <fpage>1137</fpage>&#x2013;<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.t01-1-01061.x</pub-id> </citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>SriRamaratnam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Welsch</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Viswanathan</surname>
<given-names>V. S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Regulation of Ferroptotic Cancer Cell Death by GPX4</article-title>. <source>Cell</source> <volume>156</volume>, <fpage>317</fpage>&#x2013;<lpage>331</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.12.010</pub-id> </citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Ferroptosis: Death by Lipid Peroxidation</article-title>. <source>Trends Cel Biol.</source> <volume>26</volume>, <fpage>165</fpage>&#x2013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2015.10.014</pub-id> </citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W. S.</given-names>
</name>
<name>
<surname>Stockwell</surname>
<given-names>B. R.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Synthetic Lethal Screening Identifies Compounds Activating Iron-dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells</article-title>. <source>Chem. Biol.</source> <volume>15</volume>, <fpage>234</fpage>&#x2013;<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2008.02.010</pub-id> </citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>N. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Free Radical Lipid Peroxidation: Mechanisms and Analysis</article-title>. <source>Chem. Rev.</source> <volume>111</volume>, <fpage>5944</fpage>&#x2013;<lpage>5972</lpage>. <pub-id pub-id-type="doi">10.1021/cr200084z</pub-id> </citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Ferroptosis Was More Initial in Cell Death Caused by Iron Overload and its Underlying Mechanism in Parkinson&#x27;s Disease</article-title>. <source>Free Radic. Biol. Med.</source> <volume>152</volume>, <fpage>227</fpage>&#x2013;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.03.015</pub-id> </citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Role of Lipid Peroxidation Derived 4-hydroxynonenal (4-HNE) in Cancer: Focusing on Mitochondria</article-title>. <source>Redox Biol.</source> <volume>4</volume>, <fpage>193</fpage>&#x2013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2014.12.011</pub-id> </citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zille</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karuppagounder</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gough</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Bertin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Finger</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Neuronal Death after Hemorrhagic Stroke <italic>In Vitro</italic> and <italic>In Vivo</italic> Shares Features of Ferroptosis and Necroptosis</article-title>. <source>Stroke</source> <volume>48</volume>, <fpage>1033</fpage>&#x2013;<lpage>1043</lpage>. <pub-id pub-id-type="doi">10.1161/strokeaha.116.015609</pub-id> </citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Palte</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Deik</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>J.&#x20;K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A GPX4-dependent Cancer Cell State Underlies the clear-cell Morphology and Confers Sensitivity to Ferroptosis</article-title>. <source>Nat. Commun.</source> <volume>10</volume>, <fpage>1617</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-09277-9</pub-id> </citation>
</ref>
</ref-list>
<sec id="s8">
<title>Glossary</title>
<def-list>
<def-item>
<term id="G1-fphar.2021.657033">ROS</term>
<def>
<p>reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term id="G2-fphar.2021.657033">DFO</term>
<def>
<p>deferoxamine</p>
</def>
</def-item>
<def-item>
<term id="G3-fphar.2021.657033">PUFA,</term>
<def>
<p>polyunsaturated fatty&#x20;acid</p>
</def>
</def-item>
<def-item>
<term id="G4-fphar.2021.657033">PL</term>
<def>
<p>phospholipid</p>
</def>
</def-item>
<def-item>
<term id="G5-fphar.2021.657033">
<italic>RPL8</italic>
</term>
<def>
<p>ribosomal protein L8</p>
</def>
</def-item>
<def-item>
<term id="G6-fphar.2021.657033">
<italic>IREB2</italic>
</term>
<def>
<p>iron response element binding protein&#x20;2</p>
</def>
</def-item>
<def-item>
<term id="G7-fphar.2021.657033">
<italic>ATP5G3</italic>
</term>
<def>
<p>ATP synthase F0 complex subunit&#x20;C3</p>
</def>
</def-item>
<def-item>
<term id="G8-fphar.2021.657033">
<italic>CS</italic>
</term>
<def>
<p>citrate synthase</p>
</def>
</def-item>
<def-item>
<term id="G9-fphar.2021.657033">
<italic>TTC35</italic>
</term>
<def>
<p>tetratricopeptide repeat domain&#x20;35</p>
</def>
</def-item>
<def-item>
<term id="G10-fphar.2021.657033">
<italic>ACSF2</italic>
</term>
<def>
<p>acyl-CoA synthetase family member&#x20;2</p>
</def>
</def-item>
<def-item>
<term id="G11-fphar.2021.657033">
<italic>HSPB1</italic>
</term>
<def>
<p>heat shock protein &#x3b2;-1</p>
</def>
</def-item>
<def-item>
<term id="G12-fphar.2021.657033">
<italic>PTGS2</italic>
</term>
<def>
<p>prostaglandin-endoperoxide synthase 2</p>
</def>
</def-item>
<def-item>
<term id="G13-fphar.2021.657033">CNS</term>
<def>
<p>central nervous system</p>
</def>
</def-item>
<def-item>
<term id="G14-fphar.2021.657033">LOOH</term>
<def>
<p>lipid hydroperoxide</p>
</def>
</def-item>
<def-item>
<term id="G15-fphar.2021.657033">GSH</term>
<def>
<p>glutathione</p>
</def>
</def-item>
<def-item>
<term id="G16-fphar.2021.657033">CoQ<sub>10</sub>
</term>
<def>
<p>coenzyme Q<sub>10</sub>
</p>
</def>
</def-item>
<def-item>
<term id="G17-fphar.2021.657033">4-HNE</term>
<def>
<p>4-hydroxy-2-nonenal</p>
</def>
</def-item>
<def-item>
<term id="G18-fphar.2021.657033">MDA</term>
<def>
<p>malondialdehyde</p>
</def>
</def-item>
<def-item>
<term id="G19-fphar.2021.657033">SFA</term>
<def>
<p>saturated fatty&#x20;acid</p>
</def>
</def-item>
<def-item>
<term id="G20-fphar.2021.657033">MUFA</term>
<def>
<p>monounsaturated fatty&#x20;acid</p>
</def>
</def-item>
<def-item>
<term id="G21-fphar.2021.657033">AA</term>
<def>
<p>arachidonic&#x20;acid</p>
</def>
</def-item>
<def-item>
<term id="G22-fphar.2021.657033">AdA</term>
<def>
<p>adrenic&#x20;acid</p>
</def>
</def-item>
<def-item>
<term id="G23-fphar.2021.657033">PE</term>
<def>
<p>phosphatidylethanolamine</p>
</def>
</def-item>
<def-item>
<term id="G24-fphar.2021.657033">ACSL4</term>
<def>
<p>acyl-CoA synthetase long-chain family member&#x20;4</p>
</def>
</def-item>
<def-item>
<term id="G25-fphar.2021.657033">LPCAT3</term>
<def>
<p>lysophosphatidylcholine acyltransferase 3</p>
</def>
</def-item>
<def-item>
<term id="G26-fphar.2021.657033">TZD</term>
<def>
<p>thiazolidinedione</p>
</def>
</def-item>
<def-item>
<term id="G27-fphar.2021.657033">TRO</term>
<def>
<p>troglitazone</p>
</def>
</def-item>
<def-item>
<term id="G28-fphar.2021.657033">PIO</term>
<def>
<p>pioglitazone</p>
</def>
</def-item>
<def-item>
<term id="G29-fphar.2021.657033">ROSI</term>
<def>
<p>rosiglitazone</p>
</def>
</def-item>
<def-item>
<term id="G30-fphar.2021.657033">LOX</term>
<def>
<p>lipoxygenase</p>
</def>
</def-item>
<def-item>
<term id="G31-fphar.2021.657033">L&#x00B7;</term>
<def>
<p>pentadienyl radical</p>
</def>
</def-item>
<def-item>
<term id="G32-fphar.2021.657033">&#x00B7;OH</term>
<def>
<p>hydroxyl radicals</p>
</def>
</def-item>
<def-item>
<term id="G33-fphar.2021.657033">LO&#x00B7;</term>
<def>
<p>alkoxy groups</p>
</def>
</def-item>
<def-item>
<term id="G34-fphar.2021.657033">HO<sub>2</sub>&#x00B7;</term>
<def>
<p>hydroperoxyl radicals</p>
</def>
</def-item>
<def-item>
<term id="G35-fphar.2021.657033">LOO&#x00B7;</term>
<def>
<p>peroxy radical</p>
</def>
</def-item>
<def-item>
<term id="G36-fphar.2021.657033">H<sub>2</sub>O<sub>2</sub>
</term>
<def>
<p>hydrogen peroxide</p>
</def>
</def-item>
<def-item>
<term id="G37-fphar.2021.657033">RTA</term>
<def>
<p>radical trapping antioxidant</p>
</def>
</def-item>
<def-item>
<term id="G38-fphar.2021.657033">Fer-1</term>
<def>
<p>ferrostatin-1</p>
</def>
</def-item>
<def-item>
<term id="G39-fphar.2021.657033">Lip-1</term>
<def>
<p>liproxstatin-1</p>
</def>
</def-item>
<def-item>
<term id="G40-fphar.2021.657033">Tf</term>
<def>
<p>transferrin</p>
</def>
</def-item>
<def-item>
<term id="G41-fphar.2021.657033">TfR</term>
<def>
<p>transferrin receptor</p>
</def>
</def-item>
<def-item>
<term id="G42-fphar.2021.657033">DMT1</term>
<def>
<p>divalent metal transporter&#x20;1</p>
</def>
</def-item>
<def-item>
<term id="G43-fphar.2021.657033">LIP</term>
<def>
<p>labile iron&#x20;pool</p>
</def>
</def-item>
<def-item>
<term id="G44-fphar.2021.657033">FT</term>
<def>
<p>ferritin</p>
</def>
</def-item>
<def-item>
<term id="G45-fphar.2021.657033">FTH1</term>
<def>
<p>ferritin heavy chain&#x20;1</p>
</def>
</def-item>
<def-item>
<term id="G46-fphar.2021.657033">FTL</term>
<def>
<p>ferritin light&#x20;chain</p>
</def>
</def-item>
<def-item>
<term id="G47-fphar.2021.657033">NCOA4</term>
<def>
<p>nuclear receptor coactivator&#x20;4</p>
</def>
</def-item>
<def-item>
<term id="G48-fphar.2021.657033">FPN</term>
<def>
<p>ferroportin</p>
</def>
</def-item>
<def-item>
<term id="G49-fphar.2021.657033">GPX4</term>
<def>
<p>glutathione peroxidase 4</p>
</def>
</def-item>
<def-item>
<term id="G50-fphar.2021.657033">Se</term>
<def>
<p>selenium</p>
</def>
</def-item>
<def-item>
<term id="G51-fphar.2021.657033">L-OH</term>
<def>
<p>lipid alcohol</p>
</def>
</def-item>
<def-item>
<term id="G52-fphar.2021.657033">RSL3</term>
<def>
<p>Ras-selective lethal 3</p>
</def>
</def-item>
<def-item>
<term id="G53-fphar.2021.657033">Sec</term>
<def>
<p>selenocysteine</p>
</def>
</def-item>
<def-item>
<term id="G54-fphar.2021.657033">Glu</term>
<def>
<p>glutamate</p>
</def>
</def-item>
<def-item>
<term id="G55-fphar.2021.657033">Cys</term>
<def>
<p>cysteine</p>
</def>
</def-item>
<def-item>
<term id="G56-fphar.2021.657033">Gly</term>
<def>
<p>glycine</p>
</def>
</def-item>
<def-item>
<term id="G57-fphar.2021.657033">BSO</term>
<def>
<p>buthionine sulfoximine</p>
</def>
</def-item>
<def-item>
<term id="G58-fphar.2021.657033">GCL</term>
<def>
<p>glutamate-cysteine ligase</p>
</def>
</def-item>
<def-item>
<term id="G59-fphar.2021.657033">IPP</term>
<def>
<p>isopentenyl pyrophosphate</p>
</def>
</def-item>
<def-item>
<term id="G60-fphar.2021.657033">SQS</term>
<def>
<p>squalene synthase</p>
</def>
</def-item>
<def-item>
<term id="G61-fphar.2021.657033">HMG-CoA</term>
<def>
<p>3-hydroxy-3-methyl glutaryl-coenzyme A</p>
</def>
</def-item>
<def-item>
<term id="G62-fphar.2021.657033">HMGCR</term>
<def>
<p>HMG-CoA reductase</p>
</def>
</def-item>
<def-item>
<term id="G63-fphar.2021.657033">FSP1</term>
<def>
<p>ferroptosis suppressor protein&#x20;1</p>
</def>
</def-item>
<def-item>
<term id="G64-fphar.2021.657033">NRF2</term>
<def>
<p>nuclear factor erythroid 2-related factor&#x20;2</p>
</def>
</def-item>
<def-item>
<term id="G65-fphar.2021.657033">TXNRD1</term>
<def>
<p>thioredoxin reductase 1</p>
</def>
</def-item>
<def-item>
<term id="G66-fphar.2021.657033">NADK</term>
<def>
<p>NAD<sup>&#x2b;</sup> kinase</p>
</def>
</def-item>
<def-item>
<term id="G67-fphar.2021.657033">NOX</term>
<def>
<p>NADPH oxidase</p>
</def>
</def-item>
<def-item>
<term id="G68-fphar.2021.657033">DPI</term>
<def>
<p>diphenylene iodonium</p>
</def>
</def-item>
<def-item>
<term id="G69-fphar.2021.657033">TCA cycle</term>
<def>
<p>tricarboxylic acid&#x20;cycle</p>
</def>
</def-item>
<def-item>
<term id="G70-fphar.2021.657033">Keap1</term>
<def>
<p>Kelch-like ECH-associated protein</p>
</def>
</def-item>
<def-item>
<term id="G71-fphar.2021.657033">
<italic>NQO1</italic>
</term>
<def>
<p>NAD(P)H quinone oxidoreductase-1</p>
</def>
</def-item>
<def-item>
<term id="G72-fphar.2021.657033">
<italic>HO1</italic>
</term>
<def>
<p>heme oxygenase-1</p>
</def>
</def-item>
<def-item>
<term id="G73-fphar.2021.657033">ARF</term>
<def>
<p>auxin response factor</p>
</def>
</def-item>
<def-item>
<term id="G74-fphar.2021.657033">FOCAD</term>
<def>
<p>focadhesin</p>
</def>
</def-item>
<def-item>
<term id="G75-fphar.2021.657033">FAK</term>
<def>
<p>focal adhesion kinase</p>
</def>
</def-item>
<def-item>
<term id="G76-fphar.2021.657033">OHSC</term>
<def>
<p>organotypic hippocampal slice culture</p>
</def>
</def-item>
<def-item>
<term id="G77-fphar.2021.657033">PD</term>
<def>
<p>Parkinson&#x2019;s disease</p>
</def>
</def-item>
<def-item>
<term id="G78-fphar.2021.657033">AD</term>
<def>
<p>Alzheimer&#x2019;s disease</p>
</def>
</def-item>
<def-item>
<term id="G79-fphar.2021.657033">HD</term>
<def>
<p>Huntington&#x2019;s disease</p>
</def>
</def-item>
<def-item>
<term id="G80-fphar.2021.657033">ICH</term>
<def>
<p>intracerebral hemorrhage</p>
</def>
</def-item>
<def-item>
<term id="G81-fphar.2021.657033">MCAO</term>
<def>
<p>middle cerebral artery occlusion</p>
</def>
</def-item>
<def-item>
<term id="G82-fphar.2021.657033">Hb</term>
<def>
<p>hemoglobin</p>
</def>
</def-item>
<def-item>
<term id="G83-fphar.2021.657033">SNpc</term>
<def>
<p>substantia nigra pars compacta</p>
</def>
</def-item>
<def-item>
<term id="G84-fphar.2021.657033">FAC</term>
<def>
<p>ferric ammonium citrate</p>
</def>
</def-item>
<def-item>
<term id="G85-fphar.2021.657033">MPTP</term>
<def>
<p>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p>
</def>
</def-item>
<def-item>
<term id="G86-fphar.2021.657033">A&#x3b2;</term>
<def>
<p>amyloid-&#x3b2;</p>
</def>
</def-item>
<def-item>
<term id="G87-fphar.2021.657033">NFT</term>
<def>
<p>neurofibrillary tangle</p>
</def>
</def-item>
<def-item>
<term id="G88-fphar.2021.657033">HP</term>
<def>
<p>hippocampi</p>
</def>
</def-item>
<def-item>
<term id="G89-fphar.2021.657033">FC</term>
<def>
<p>frontal cortices</p>
</def>
</def-item>
<def-item>
<term id="G90-fphar.2021.657033">CDDO</term>
<def>
<p>2-cyano-3,12-dioxooleana-1,9-dien-28-oic&#x20;acid</p>
</def>
</def-item>
<def-item>
<term id="G91-fphar.2021.657033">ARE</term>
<def>
<p>antioxidant response element</p>
</def>
</def-item>
</def-list>
</sec>
</back>
</article>